The estimated Net Worth of James F Tessmer is at least $788 mil dollars as of 15 March 2021. Mr. Tessmer owns over 22,912 units of Lexicon Pharmaceuticals Inc stock worth over $121,285 and over the last 16 years he sold LXRX stock worth over $158,551. In addition, he makes $508,342 as Vice President - Finance and Accounting at Lexicon Pharmaceuticals Inc.
James has made over 7 trades of the Lexicon Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 22,912 units of LXRX stock worth $158,551 on 15 March 2021.
The largest trade he's ever made was exercising 28,316 units of Lexicon Pharmaceuticals Inc stock on 28 February 2021 worth over $47,854. On average, James trades about 3,069 units every 57 days since 2009. As of 15 March 2021 he still owns at least 71,766 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Mr. Tessmer stock trades at the bottom of the page.
James F. Tessmer serves as Vice President - Finance and Accounting of the Company. He has been our vice president, finance and accounting since November 2007 and previously served in a series of finance and accounting leadership positions since joining our company in 2001. Mr. Tessmer was previously assistant controller for Mariner Health Network, Inc. and prior to that served in a variety of financial and accounting management positions for HWC Distribution Corp. and American General Corporation. Mr. Tessmer is a certified public accountant and received his B.B.A. from the University of Wisconsin – Milwaukee and his M.B.A. from the University of Houston.
As the Vice President - Finance and Accounting of Lexicon Pharmaceuticals Inc, the total compensation of James Tessmer at Lexicon Pharmaceuticals Inc is $508,342. There are 9 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.
James Tessmer is 60, he's been the Vice President - Finance and Accounting of Lexicon Pharmaceuticals Inc since 2009. There are 11 older and 7 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.
James's mailing address filed with the SEC is 8800 TECHNOLOGY FOREST PLACE, , THE WOODLANDS, TX, 77381.
Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc... y Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: